Mersana Therapeutics, Inc. (MRSN)
NASDAQ: MRSN · Real-Time Price · USD
1.310
-0.060 (-4.38%)
Jan 8, 2025, 12:14 PM EST - Market open
Mersana Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for MRSN stock have an average target of 6.00, with a low estimate of 3.00 and a high estimate of 9.00. The average target predicts an increase of 358.02% from the current stock price of 1.31.
Analyst Consensus: Buy
* Price targets were last updated on Aug 27, 2024.
Analyst Ratings
The average analyst rating for MRSN stock from 6 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 3 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 6 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Maintains $6 → $5 | Strong Buy | Maintains | $6 → $5 | +281.68% | Aug 27, 2024 |
| Baird | Baird | Hold Maintains $4 → $3 | Hold | Maintains | $4 → $3 | +129.01% | Aug 14, 2024 |
| JP Morgan | JP Morgan | Sell → Hold Upgrades $5 | Sell → Hold | Upgrades | $5 | +281.68% | Mar 19, 2024 |
| Wedbush | Wedbush | Hold → Buy Upgrades $2 → $7 | Hold → Buy | Upgrades | $2 → $7 | +434.35% | Feb 29, 2024 |
| Truist Securities | Truist Securities | Hold → Strong Buy Upgrades $9 | Hold → Strong Buy | Upgrades | $9 | +587.02% | Feb 29, 2024 |
Financial Forecast
Revenue This Year
32.38M
from 36.86M
Decreased by -12.14%
Revenue Next Year
27.76M
from 32.38M
Decreased by -14.29%
EPS This Year
-0.61
from -1.48
EPS Next Year
-0.59
from -0.61
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 38.6M | 52.5M | 210.0M | |||
| Avg | 32.4M | 27.8M | 49.5M | |||
| Low | 24.6M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 4.6% | 62.1% | 656.6% | |||
| Avg | -12.1% | -14.3% | 78.4% | |||
| Low | -33.2% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -0.56 | -0.22 | -0.48 | |||
| Avg | -0.61 | -0.59 | -0.72 | |||
| Low | -0.65 | -0.78 | -0.93 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.